Oxford Immunotec Global (Oxford Immunotec Global) LT-Debt-to-Total-Asset : 0.03 (As of Sep. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Oxford Immunotec Global LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Oxford Immunotec Global's long-term debt to total assests ratio for the quarter that ended in Sep. 2020 was 0.03.

Oxford Immunotec Global's long-term debt to total assets ratio increased from Sep. 2019 (0.03) to Sep. 2020 (0.03). It may suggest that Oxford Immunotec Global is progressively becoming more dependent on debt to grow their business.

Oxford Immunotec Global LT-Debt-to-Total-Asset Historical Data

The historical data trend for Oxford Immunotec Global's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Immunotec Global LT-Debt-to-Total-Asset Chart

Oxford Immunotec Global Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.24

0.21

0.03

Oxford Immunotec Global Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.03	0.03

Oxford Immunotec Global LT-Debt-to-Total-Asset Calculation

Oxford Immunotec Global's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

LT Debt to Total Assets (A: Dec. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2019 )	/	Total Assets (A: Dec. 2019 )
	=	7.742	/	235.252
	=	0.03

Oxford Immunotec Global's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2020 is calculated as

LT Debt to Total Assets (Q: Sep. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2020 )	/	Total Assets (Q: Sep. 2020 )
	=	7.19	/	210.5
	=	0.03

Oxford Immunotec Global (NAS:OXFD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Oxford Immunotec Global LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Oxford Immunotec Global's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford Immunotec Global (Oxford Immunotec Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Oxford Immunotec Global PLC (NAS:OXFD) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

143 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4SE

Website

http://www.oxfordimmunotec.com

Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.

Executives

Andrew Scott Walton	director	430 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark R. Klausner	director	C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Patricia Randall	director	C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Richard A Sandberg	director	330 NEVEDA STREET, NEWTON MA 02460-1458
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008
Peter Wrighton-smith	director, officer: Chief Executive Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Mclaughlin Matthew T E	officer: Chief Financial Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Stefan C Linn	officer: Chief Operating Officer	C/O OXFORD IMMUNOTEC GLOBAL 940 INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Janet Louise Kidd	officer: General Counsel	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Elizabeth M Keiley	officer: SVP & General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Richard M. Altieri	officer: Chief Financial Officer	C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Richard Wenstrup	officer: Chief Medical Officer	C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RZ